Holmium laser enucleation follows the natural surgical plane between the enlarged adenoma and the prostate capsule. The adenoma is released into the bladder, morcellated, removed, and sent for pathology.
The operation's clinical strength is size independence. Its access limitation is a demanding learning curve. A directory entry that merely says “laser prostate surgery” is not enough; patients need to know whether a surgeon actually performs complete anatomic enucleation and at what volume.
Why size independence matters
HoLEP can treat small, moderate, large, and very large glands, including middle lobes. In large-gland randomized comparisons, it provides strong symptom and flow improvement with lower retreatment than partial resection approaches.
It can also be used after prior BPH procedures, although implants, scarring, prior radiation, and altered planes increase complexity. Prior UroLift implants may be encountered during enucleation and can interfere with morcellation equipment.
The outcomes patients should ask the surgeon to own
Published averages cannot substitute for local outcomes during a steep learning curve. A mature HoLEP program should track conversion, capsular perforation, transfusion, clot retention, ureteral injury, stricture, bladder-neck contracture, persistent stress incontinence, readmission, and retreatment.
Case volume alone is not perfect, but it is useful. Ask how many independent cases the surgeon has completed, whether mentorship or fellowship training was used, and how outcomes changed after the learning phase.
Continence and sexual function
Temporary stress leakage is more common than after some lower-burden treatments, especially with very large glands, pre-existing sphincter weakness, older age, or a technically difficult apex. Most temporary leakage improves, but persistent incontinence is an important risk to quantify locally.
Standard HoLEP commonly causes dry or retrograde ejaculation. Erections are usually preserved. Ejaculation-preserving modifications exist, but they may leave more tissue and have less mature durability evidence; they should not be assumed to be equivalent to standard complete enucleation.
Recovery and pathology
Many patients stay overnight with a catheter, though same-day pathways exist. Blood, urgency, frequency, burning, fatigue, and temporary activity restrictions are expected. Pelvic-floor instruction can help patients prepare for temporary stress leakage.
A substantial specimen is available for pathologic review. Incidental prostate cancer can be found, but HoLEP does not remove the peripheral prostate and is not a prostate-cancer operation. PSA requires a new postoperative baseline.
Capability questions
- How many complete HoLEP cases has the surgeon performed independently?
- What are the program's persistent incontinence, transfusion, stricture, and readmission rates?
- How do gland size, prior UroLift, prior radiation, or urinary retention change my risk?
- What pelvic-floor and catheter pathway does the center use?
- Why HoLEP rather than Aquablation or robotic simple prostatectomy for my priorities?
Bottom line
HoLEP offers exceptional power and durability across sizes, but its real moat is surgeon capability. Verify enucleation experience rather than relying on a generic “laser” label.
Sources and evidence
Open the original guideline, regulatory record, or study. Evidence was last checked August 14, 2026.
-
AUA Guideline (2026) Part III: Procedural/Surgical Management The Journal of Urology · professional guideline · 2026
-
Disease Management — Management of Non-neurogenic Male LUTS European Association of Urology · professional guideline · 2026